Please login to the form below

Not currently logged in
Email:
Password:

CytomX

This page shows the latest CytomX news and features for those working in and with pharma, biotech and healthcare.

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

In an unusual development, CytomX also gets a stake in an unnamed T-cell engaging bispecific developed at Amgen. ... Shares in US clinical stage biopharmaceutical company CytomX leaped more than a third on the latest deal.

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    BMS has expanded its 2014 agreement with CytomX Therapeutics to access up to eight further targets in oncology and other fields, using CytomX’s Probody platform. ... 650. CytomX Therapeutics. BMS. Strategic collaboration. Probody platform to enhance

  • Deal Watch April 2016 Deal Watch April 2016

    CytomX leads. Argenx undertakes R&D until IND, AbbVie thereafter it option exercised. ... Zymeworks, like CytomX, have multiple Big Pharma partners including Merck &Co and Lilly.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    CytomX / BMS. Development and commercialisation licence. Selective monoclonal antibodies (“Probodies”) for up to 4 oncology targets.

  • Pharma deals during May 2014 Pharma deals during May 2014

    BMS also entered into a platform deal with CytomX for so-called “Probodies,” monoclonal antibodies that are selectively activated within the cancer microenvironment.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    818. CytomX / Pfizer. Collaboration and exclusive licence to selected PDCs.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • CytomX appoints Rachel Humphrey chief medical officer CytomX appoints Rachel Humphrey chief medical officer

    Former VP of Eli Lilly and AstraZeneca joins the company. CytomX Therapeutics has appointed Dr Rachel Humphrey as chief medical officer. ... She said: “Since joining the CytomX board of directors in March, I have been able to see at first-hand the

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... His new colleague Ray joined CytomX in 2011 and was instrumental in brokering the agreement with Pfizer.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics